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Abstract
Impairment of immune defenses can contribute to severe influenza infections. Rapamycin is an 
immunosuppressive drug often used to prevent transplant rejection and is currently undergoing 
clinical trials for treating cancers and autoimmune diseases. We investigated whether rapamycin 
has deleterious effects during lethal influenza viral infections. We treated mice with two 
concentrations of rapamycin and infected them with A/Puerto Rico/8/1934 (A/PR8), followed by a 
heterosubtypic A/Hong Kong/1/68 (A/HK68) challenge. Our data show similar morbidity, 
mortality, and lung viral titer with both rapamycin treatment doses compared to untreated controls, 
with a delay in morbidity onset in rapamycin high dose recipients during primary infection. 
Rapamycin treatment at high dose also led to increase in percent cytokine producing T cells in the 
spleen. However, all infected animals had similar serum antibody responses against A/PR8. Post-
A/HK68 challenge, rapamycin had no impeding effect on morbidity or mortality and had similar 
serum antibody levels against A/PR8 and A/HK68. We conclude that rapamycin treatment does 
not adversely affect morbidity, mortality, or antibody production during lethal influenza infections.
Introduction
Annual epidemics of influenza are estimated to result in about 3–5 million cases of severe 
illness, and about 250,000–500,000 deaths worldwide, with H1N1 and H3N2 as the two 
predominant Influenza A strains in humans (3). The annual attack rate of Influenza is 
estimated at 5–10% in adults and 20–30% in children. The “high risk” population most 
likely to have illness resulting in hospitalization includes those with impaired immune 
defenses such as children less than 5 years old, adults more than 65 years old, pregnant 
women, and individuals with a weakened immune system due to disease or medication 
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(3,32). These populations are particularly susceptible to influenza morbidity and mortality, 
and despite reduced vaccine efficacy in immunocompromised individuals, annual 
vaccination is nonetheless recommended for immunosuppressed groups (6,12,20).
Among different types of immunosuppression, the drug-induced form of 
immunosuppression has the potential to make patients more susceptible to severe influenza 
illness (6,20) and is, therefore, an important public health issue that needs to be investigated. 
Some studies using animal models have, however, not shown such compromising effects 
during infections in conjunction with immunomodulatory therapies. A study using 
rosuvastatin showed no difference in influenza A infection clinical course and viral 
replication (26). Others have shown ameliorative effects through suppression of cytokine 
storm (30) and inhibition of Nox2 oxidase activity (29). Inhibition of the mammalian target 
of rapamycin (mTOR) has also improved immunological outcomes in experimental animals 
(1,11,17,24) and clinically (21). In addition, inhibitors of mTOR have been shown to be 
beneficial in the absence of infection, such as with influenza vaccine response in humans 
(31) and increasing lifespan in mice (4,16).
Rapamycin (Sirolimus) was approved in 1999 by the FDA to prevent transplant rejection by 
inhibiting mTOR (10) and is currently in clinical trials for treating a variety of different 
cancers and autoimmune diseases, highlighting the broad scope of its therapeutic effects 
(14,23,33). mTOR is a key member of a cellular pathway that senses the environment for 
optimal cell proliferation. The specific target for rapamycin, the mTORC1 complex, is 
responsible for two main phosphorylation events with p70 ribosomal S6 kinase (p70S6K) 
and the binding protein eukaryotic translation initiation factor eIF4E (4E-BP1), resulting in 
transcription and translation needed for cell growth, metabolism, and autophagy (13,22,33). 
The reduced nephrotoxic effects compared to other immunosuppressive drugs have 
underscored mTOR inhibitors as a more attractive option for transplant recipients (2).
The humoral response is a key component of the immune response against influenza 
(7,8,18). The immunogenicity of a vaccine is often determined by assessing serum levels of 
antiflu antibodies, but immunocompromised individuals have been shown to possess lower 
titers following vaccination compared with healthy controls (6). We, therefore, investigated 
whether daily treatment of mice with rapamycin compromises induction of protective 
humoral immune response to a primary lethal H1N1 influenza infection and a subsequent 
heterosubtypic H3N2 virus challenge.
Materials and Methods
Mice, treatment, and viral infection
Six-week-old C57BL/6 mice (Jackson Laboratories) were treated intraperitoneally (i.p.) 
daily (d) for the duration of the experiment with 500 μL of phosphate-buffered saline (PBS) 
containing 12 μg (high dose) or 1.5 μg (low dose) rapamycin (Rapamune oral solution, 1 
mg/mL sirolimus; Pfizer) as described previously (1,11,17). Three days after treatment was 
initiated, mice were inoculated intranasally (i.n.) with 1.5 LD50 of A/Puerto Rico/8/1934 (A/
PR8) (H1N1) under avertin anesthesia (Supplementary Fig. S1A; Supplementary Data are 
available online at www.liebertpub.com/vim). Mice were monitored daily postinoculation 
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for morbidity (weight loss) and mortality. All mice that lost 25% or greater body weight as 
determined by preinfection weight were humanely euthanized as per CDC-IACUC 
guidelines. Lungs were collected 6, 9, and 12 days and sera were collected 2 and 5 weeks 
postinoculation. Five to six weeks later, mice were challenged with a heterosubtypic virus, 
A/Hong Kong/1/68 (A/HK68) (H3N2), at 5 LD50. All animal research conducted in this 
study was approved by the CDC-IACUC and was conducted in an AAALAC-accredited 
facility.
Lung collection and analysis
As described previously (28), lungs were collected, frozen (−80°C), homogenized, and 
clarified before serial titration in 10- to 11-day-old embryonated hen eggs. The inoculated 
eggs were incubated at 37°C for 48 h. Allantoic fluid was collected and titrated by 
hemagglutination assay and viral titers were expressed as the 50% egg infectious dose 
(EID50).
Serum collection and analysis
Blood was collected in SST Microtainer tubes (Becton, Dickinson & Company) using 
mandibular bleeds. Serum was isolated by centrifugation and frozen at −40°C until testing. 
Serum was treated with Receptor Destroying Enzyme (Denka Seiken Company) at 1:4 ratio 
and incubated for 18 h at 37°C and at 56°C for 30 min.
Virus-specific ELISA was performed by coating flat-bottom immuno 96-well plates (Fisher) 
overnight with 50 hemagglutinin units (HAU) of homologous virus in 50 μL per well. After 
blocking with 4% BSA (Sigma-Aldrich) in 1×PBS/0.05% Tween (PBST) (Gibco, Life 
Technologies), serum was serial diluted twofold or fourfold from 1:100 dilution and 
secondary HRP-conjugated anti-IgM or IgG (Southern Biotech) was added, respectively. 
After PBST wash, 3,3′,5,5′-Tetramethylbenzidine (TMB) (eBioscience) and Stop solution 
(Kirkegaard & Perry) (50 μL) were added at a 1:1 ratio. ELISA background was subtracted, 
and endpoint titers with optical density (OD) values reaching ≥0.1 were plotted. The limit of 
detection for ELISA titers was 3.32 log4 units for IgG and 6.64 log2 units for IgM. 
Hemagglutination inhibition (HI) assay with 1% turkey red blood cells was performed as 
previously described (27). The limit of detection for HI titers was 2.32 log2 HI units/mL.
Intracellular cytokine assay
On day 35 (5 weeks) postinfection, single cell suspensions from mouse spleen were 
prepared in MACS buffer (500 mL PBS, 2.5 mL fetal bovine serum, and 2 mL EDTA) using 
a cell strainer (VWR). T cells and intracellular cytokine (IFNγ and TNFα) staining after in 
vitro stimulation of 106 splenocytes/well for 15 h with 0.1 multiplicity of infection of virus 
were analyzed using Alexa Fluor 700-anti-CD8, PE-Cy7-anti-CD4, PerCP-Cy5.5-anti-IFNγ, 
and APC-anti-TNFα following the manufacturer’s recommendations. Approximately, 105 
cells were acquired and analyzed on a BD LSRFortessa flow cytometer (BD Bioscience). 
Data were analyzed with FlowJo software (Tree Star).
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Western blot
A549 cells were treated overnight with two different batches of Rapamycin at equivalent 
dose per volume used within mice weighing 20 g. P70 S6 Kinase phosphorylation (Thr389) 
was induced using Actinomycin D (Sigma-Aldrich), and anti-p70 S6 phosphorylation-
specific 108D2 antibody (108D2; Cell Signaling) was used for detection, as described 
previously (19).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software). 
Comparisons were made among infected animals undergoing different treatments (indicated 
on graphs). Nonparametric one-way analysis of variance Kruskal–Wallis test with Dunn’s 
post-test was used for analysis of virus titer, ELISA, and HI assay. The Student t-test was 
used to analyze flow cytometry. Survival curves were analyzed using Kaplan–Meier test. All 
differences were considered statistically significant when the p-value was ≤0.05.
Results
To address the effect of high and low dose of daily rapamycin treatments during a lethal 
influenza virus infection, as shown in Supplementary Figure S1, we treated mice with two 
concentrations of the drug (12 or 1.5 μg/d in 500 μL PBS). Function of rapamycin was 
confirmed by assessing phosphorylation resulting from the activation of the mTOR pathway. 
As described in the Materials and Methods section, Actinomycin D was added to the A549 
cell culture to ensure mTOR activation. Phosphorylation of p70 S6 Kinase, downstream of 
mTOR signaling, was absent with the addition of rapamycin used in the studies herein 
(Supplementary Fig. S1B). Intraperitoneal rapamycin treatments in mice began 3 days 
before infection while controls were only given PBS. We inoculated mice i.n. with 1.5 LD50 
of A/PR8 virus (H1N1) as a primary infection on day 0, while control groups were 
administered PBS alone. Each group was subsequently divided into two subgroups, 
receiving either a heterosubtypic challenge with 5 LD50 A/HK68 virus (H3N2) or PBS 
(Supplementary Fig. S1A) to assess whether rapamycin treatments interfere with the 
induction of cross-protective responses against an antigenically distinct virus.
Following A/PR8 inoculation, similar morbidities were observed in animals treated with 
high and low concentrations of rapamycin compared to infected control animals (Fig. 1A, 
left panel). A significant (p ≤ 0.01) delay, however, was observed during the onset of 
morbidity in infected animals treated with a high concentration of rapamycin reaching 
12.5% weight loss (the midway point between 100% and 75% weight) ~2 days after no or 
low rapamycin treated mice (Fig. 1A, middle panel). Despite this delay, comparable levels of 
lethality were observed among all mice challenged with A/PR8 virus, regardless of 
rapamycin dose (Fig. 1A, right panel). Furthermore, viral titers in lungs collected at days 6, 
9, and 12 post A/PR8 inoculation were similar among infected-animal groups, with no 
significant difference (Supplementary Fig. S2). In summary, our data suggest that rapamycin 
does not exacerbate morbidity, mortality, or increase lung viral titers during a lethal A/PR8 
infection, but rather contributes to delays in the onset of morbidity and recovery among 
infected animals.
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Next, we examined the effect of rapamycin treatment on the induction of A/PR8-specific 
antibody levels following primary A/PR8 virus infection. We observed no significant 
differences in HI titers among infected animals with or without rapamycin treatments (Fig. 
1B). Similarly, we observed no significant difference in A/PR8-specific IgG or IgM levels 
among infected animals receiving no, low, or high dose rapamycin treatments in serum 
collected 2 and 5 weeks postinfection (Fig. 1C). However, compared to A/PR8 infected 
mice, at day 35 postinfection, ex vivo analysis of cytokine producing T-cell subsets in high 
dose rapamycin treated A/PR8 infected mice spleen showed a significant increase in IFNγ+ 
CD4 T cells, TNFα+ CD4T cells, and IFNγ+ CD8 T cells (Fig. 1D).
Heterosubtypic immunity is crucial in conferring protection against an antigenically distinct 
virus (9,25). To test whether rapamycin treatments interfere with heterosubtypic immunity, 
we challenged animals 5–6 weeks post A/PR8 infection with 5 LD50 of an H3N2 virus (A/
HK68). Mice exposed to the A/PR8 lethal infection, with or without having undergone daily 
rapamycin treatments, did not exhibit morbidity or mortality following a lethal challenge 
with A/HK68 virus (Fig. 2A, left and right panels). Finally, serum levels of anti-A/PR8 and 
anti-A/HK68 antibodies were assessed 2 weeks post A/HK68 challenge. Animals with 
previous exposure to A/PR8 continued to maintain their elevated A/PR8 HI titers 
postchallenge (Fig. 2B, top panel). Among A/PR8 inoculated animals postchallenge, a 
significant increase in A/HK68-specific HI titers was observed in A/HK68-infected mice 
compared to their nonchallenged counterparts treated with no (p ≤ 0.001), low (p ≤ 0.0001), 
or high (p ≤ 0.0001) rapamycin (Fig. 2B, bottom panel). These elevated titers, however, were 
similar among A/HK68-infected animals, previously exposed toA/PR8, compared to each 
other. Before challenge, no animals showed detectable A/HK68 HI titers (data not shown). 
These findings indicate that rapamycin treatments did not impede induction of antibody 
titers after lethal primary infection and subsequent heterosubtypic viral challenge and did 
not enhance susceptibility to influenza compared to the infected animals not receiving daily 
rapamycin treatments.
Discussion
Medically-induced immunosuppression can compromise an individual’s ability to respond to 
pathogens. In the study herein, we assessed whether rapamycin compromises induction of 
antibody responses to lethal influenza infections in mice. Our data indicate that rapamycin 
treatments, despite an increase in cytokine producing T cells, result in similar morbidity, 
mortality, and antibody responses in A/PR8 and A/HK68-infected animals. Overall, 
rapamycin did not impede susceptibility or induction of protective antibody responses to 
lethal H1N1 and H3N2 infections.
Several studies have used low dose (1,11,17) and high dose of rapamycin i.p. treatments 
(1,24) in experimental animal models and have shown the resulting blood levels to be 5–20 
and 40–100 ng/mL, respectively (1). At both high and low dose of rapamycin treatment, we 
did not observe changes in body weight resulting from these treatments alone. However, 
among the infected groups, a delay in the onset of morbidity was observed in those treated 
with the high dose rapamycin. This delay was not reflected in overall morbidity, mortality, or 
viral clearance among infected animals. Furthermore, HA-specific neutralizing and virus-
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specific IgG and IgM antibodies were comparable among infected animals despite the daily 
treatments of rapamycin. Moreover, upon heterosubtypic virus challenge, cross-protective 
immunity was maintained with both high and low dose daily rapamycin treatments.
Despite its well established application as an immunosuppressant in clinical settings and a 
suppressor of T-cell proliferation in vitro (5), rapamycin treatment has also been shown to 
enhance T-cell function in experimental models such as with bacterial (11,24) and viral 
infections (1). Enhanced T-cell function was also observed in our studies, particularly in 
mice treated with high dose rapamycin. However, in contrast to findings from Goldberg et 
al. in which low dose rapamycin treatment led to enhanced pathogen (LCMV, Listeria, and 
West Nile virus) clearance (15), we did not see any significant differences in lung virus titer/
clearance. Although we observed a significant increase in percent influenza (nucleoprotein)-
specific CD8+ T cells (data not shown) and T-cell cytokine function in response to 
rapamycin treatment at day 35 postinfection before hetero-subtypic viral challenge, further 
studies are needed to characterize the kinetics, absolute numbers, and phenotype of CD8 T 
cells in the secondary lymphoid organs (spleen and draining lymph node) and effector sites 
such as the lungs. More recently, Keating et al. showed an enhanced protective immunity 
mediated by modification in virus-specific antibody responses in mice undergoing 
rapamycin treatments during intraperitoneal priming with influenza virus (17). In this study, 
the investigators used whole virus for immunization through intraperitoneal route along with 
one concentration (75 μg/kg) of daily rapamycin treatment. Our data are in agreement with 
this study’s results as morbidity, mortality, and HI titer resulting from lethal infection were 
unimpeded and extend these findings using two treatment concentrations of rapamycin 
during the entire course of primary lethal infection and challenge through the natural 
intranasal route of infection. We did not see lower virus-specific serum IgM antibody levels 
as reported by Keating et al., which can be due to differences in virus dose, virus subtype, 
route of virus administration, duration of rapamycin treatment in relation to virus challenge, 
and time of serum collection postinoculation.
Rapamycin treatment is typically a long-term regimen currently used to prevent graft 
rejections and may soon be used to treat a variety of cancers and autoimmune diseases 
(10,23). As a result, these treatments are likely to overlap with influenza seasons. We show 
that rapamycin treatment neither enhanced the susceptibility to nor compromised induction 
of virus-specific antibody against influenza infection in a mouse model. While our study 
focused on the role of rapamycin, patients on long-term immunosuppressive therapy receive 
a variety of immunomodulatory agents, and therefore, additional studies are warranted to 
investigate the role of rapamycin in combination with other clinically relevant drugs in the 
context of influenza virus infection. Future studies investigating the effects of rapamycin in 
the context of transplantation, autoimmune disease, or cancer on induction of protective 
immune response to influenza vaccination will allow for a greater understanding of the role 
this drug may play in “high risk” populations.
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FIG. 1. 
Morbidity, mortality, and immune responses postprimary A/PR8 infection with or without 
rapamycin treatment. (A) Morbidity (left and middle panels) and mortality (right panel), (B) 
HI assay, and (C) ELISA of serum collected 2 and 5 weeks postprimary A/PR8 infection are 
shown; mice receiving PBS (clear diamond) were given PBS i.n. and daily PBS i.p., Rapa 
High (black diamond) was given PBS i.n. and 12 μg/d rapamycin i.p., PBS+A/PR8 (clear 
circle) were given A/PR8 i.n. and daily PBS i.p., A/PR8+Rapa Low (light triangle) were 
given A/PR8 i.n. and 1.5 μg/d rapamycin i.p., and A/PR8+Rapa High (black triangle) were 
given A/PR8 i.n. and 12 μg/d rapamycin i.p. The limit of detection for HI titers was 2.32 
log2 HI units/mL. ELISA background was subtracted, and endpoint titers with OD values 
reaching ≥0.1 were graphed. The limit of detection for ELISA titers was 3.32 log4 units for 
IgG and 6.64 log2 units for IgM. (D) Cytokine producing T-cell subsets (CD4T cells and 
CD8T cells) from A/PR8 infected mice and A/PR8 infected mice treated with high dose 
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rapamycin are shown. Figure shows combined data of two independent experiments with 
eight mice per group. The difference between A/PR8 and A/PR8+Rapa groups was 
statistically significant as follows; CD4 T cells-IFNγ, *p < 0.05; CD4 T cells-TNFα, **p < 
0.005; and CD8 T cells-IFNγ, *p < 0.05. HI, hemagglutination inhibition; i.n., intranasally; 
i.p., intraperitoneally; OD, optical density; PBS, phosphate-buffered saline.
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FIG. 2. 
Morbidity, mortality, and HI titer post A/HK68 challenge with or without rapamycin 
treatment. (A) Morbidity (left panels) and mortality (right panel) and (B) HI assay of serum 
postprimary A/HK68 infection (5 LD50) are shown for PBS (clear diamond, no challenge; 
clear square, challenge), Rapa Low (light diamond, no challenge; light square, challenge), 
Rapa High (black diamond, no challenge; black square, challenge), PBS+A/PR8 (clear 
circle, no challenge; challenged, black circle), Rapa Low+A/PR8 (light inverted triangle, no 
challenge; light triangle, challenged), and Rapa High+A/PR8 (black inverted triangle, no 
challenge; black triangle, challenge) treated animals. Mortality and morbidity are 
representative graphs of three independent experiments. The limit of detection for HI titers 
was 2.32 log2 HI units/mL.
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